hydroxyurea + L-carnitine + magnesium chloride

A combination therapy consisting of hydroxyurea, L-carnitine, and magnesium chloride used primarily for the treatment of beta-thalassemia intermedia. This combination therapy appears to be more effective in improving hematologic parameters and cardiac status in patients compared to hydroxyurea alone[1]. ## Therapeutic Effects The combination therapy has shown several beneficial effects: 1. **Improved Hematologic Parameters**: Studies have demonstrated that combining hydroxyurea with L-carnitine and magnesium chloride increases mean hemoglobin and hematocrit levels during treatment[1]. 2. **Enhanced Cardiac Function**: Echocardiographic studies revealed significant improvements in cardiac status, including: - Increase in left ventricular ejection fraction[1] - Decrease in left ventricular end-diastolic diameter (with L-carnitine)[1] - Increase in pulmonary acceleration time (with magnesium)[1] ## Mechanism of Action The combination works through multiple mechanisms: - **Hydroxyurea**: An anti-cancer treatment that increases fetal hemoglobin levels, potentially reducing the need for blood transfusion in thalassemia patients[6]. - **L-Carnitine**: Has antioxidant properties and can stimulate the production of fetal hemoglobin[1]. - **Magnesium Chloride**: Helps stabilize red blood cell membranes[1]. ## Clinical Evidence A randomized controlled trial involving 120 patients with thalassemia intermedia who had been on hydroxyurea for more than 6 months compared four treatment groups[1]: - Group A: Hydroxyurea alone - Group B: Hydroxyurea and L-carnitine - Group C: Hydroxyurea and magnesium chloride - Group D: Hydroxyurea, L-carnitine, and magnesium chloride The results showed that groups B, C, and D (all combination therapies) had better outcomes than hydroxyurea alone[1]. ## Side Effects While the combination therapy shows promise, some side effects have been reported in studies of similar combinations: - Nausea and vomiting - Gastric upset - Elevated liver enzymes[5] The combination therapy of hydroxyurea with L-carnitine and magnesium chloride represents a promising approach for improving outcomes in patients with beta-thalassemia intermedia who require less frequent blood transfusions.

Other names

hydroxyurea + L-carnitine + magnesium chloride